Tesnatilimab

DB16377InvestigationalProtein Based Therapies

Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).

Mechanism: Pharmacologically active on NKG2-D type II integral membrane protein
Curator reviewed
Code names: JNJ-64304500 · NN8555 · NNC142-0002

Resolves to

Compound

UNII2B860WP9F0CAS2242758-08-1

Targets

P26718KLRK1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tesnatilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account